Baba Health Tips
Lifestyle modification is often not enough to cope with a chronic disease like diabetes. Most patients require medication to maintain a level of sugar in the vertical healthy blood. However, a major concern among physicians is a drug, the effect on the cardiovascular health of patients with diabetes. Cardiovascular disease (CVD) is a serious complication of diabetes. Heart disease and stroke are the No. 1 cause of death and disability in patients with type 2 diabetes adults with diabetes are two to four times more likely to have a heart attack and stroke compared to adults without diabetes.
Uncontrolled blood sugar can jeopardize the integrity of blood vessels, leaving them vulnerable to damage. It can also damage the nerves, causing the so-called “silent” heart attack, which does not come with the typical chest pain.
Any HbA1c test result reduction, which measures blood glucose levels over the past three months reduces the risk of heart disease, Iboleon said. A decrease of one percent means 21 percent fewer deaths from diabetes alone except for a heart attack together.
You want to ensure that the use of drugs to treat diabetes, the risk of not complicating heart attack and stroke. The use of drugs that are not only good sugar control, but also good for protecting the heart, or at least one drug that causes more damage.
Patients with type 2 diabetes are more susceptible to a heart attack or stroke due to risk factors that contribute to cardiovascular disease, including hypertension, high cholesterol and triglyceride levels, obesity, sedentary lifestyle are developed, uncontrolled blood sugar and tobacco have.
A Medicine for Diabetic Patient
Sitagliptin is a peptidase-4 inhibitor of dipeptidyl in 2006 introduced the treatment of type 2 diabetes is directed or providing benefits for CVD risk shown. The study also showed no increased incidence of hospitalization for heart failure compared to placebo.
The study, Tecos (trial evaluating cardiovascular events with sitagliptin), involved 14,671 patients from 38 countries type 2 diabetes. It was conducted in November 2008 and was completed in July last year.
The patients, all over 50 years with diabetes live, on average, 11.6 years old and have diseases such as heart attack, heart failure, stroke and blockage in the lower extremities. About 22 percent of the subjects come from Asia.
Sitagliptin, hypoglycemic drug, was tested rules in 2008 as part of the Food and Drug Administration of the United States need to be examined for cardiovascular safety anti diabetic. When a number of antidiabetic drugs were in Europe and the United States is responsible for its negative impact on the cardiovascular health of the patient.
Tecos was conducted by an independent scientific research collaboration between the Trials Unit and the Clinical Research Institute of Duke University, Oxford University and was sponsored by MSD.
At the end of the study, however, it showed that sitagliptin caused very low incidence of heart failure, not increase cardiovascular risk, without heart failure, infection, pancreatitis, cancer, kidney failure or some sugar to rise. Abraham said there was no difference between the arm and the placebo arm sitagliptin.
In general, it was found that sitagliptin was better than other drugs in the same class, because of the low rate of hospitalization for heart failure or chest pain. The incidence of pancreatic cancer was very low in both treatment groups, but he was one of those who received a rare sitagliptin.